Business
PureTech's Seaport Prices Upsized IPO Nasdaq: SPTX
PureTech Health plc announced that its founded entity, Seaport Therapeutics, has priced its upsized initial public offering of 14,160,000 shares at $18.00 per share, raising gross proceeds of $254.9 million before expenses. Seaport has also granted underwriters an option to purchase an additional 2,124,000 shares. Trading is expected to commence on the Nasdaq Global Select Market under the ticker SPTX on May 1, 2026, with the offering closing on May 4, 2026. Upon closing, PureTech Health will hold 16,685,013 shares of Seaport common stock. Disclaimer*
About this update from Puretech Health Plc
1 May 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that its Founded Entity, Seaport Therapeutics, Inc. ("Seaport"), has announced the pricing of its upsized initial public offering of 14,160,000 shares of its common stock at a price to the public of $18.00 per share, at the top of the target range. The gross proceeds to Seaport from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $254.9 million. All of the shares are being offered by Seaport. In addition, Seaport has granted the underwriters a 30-day option to buy an additional 2,124,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on May 1, 2026 under the ticker symbol "SPTX." The offering is expected to close on May 4, 2026 subject to the satisfaction of customary closing conditions. Upon the closing of the offering, PureTech will hold 16,685,013 shares of Seaport common stock. The full text of the announcement from Seaport is as follows: Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering BOSTON, April 30, 2026 - Seaport Therapeutics, Inc., (Nasdaq: SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, today announced the pricing of its upsized initial public offering of 14,160,000 shares of its common stock at a price to the public of $18.00 per share, at the top of the target range. The gross proceeds to Seaport Therapeutics from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $254.9 million. All of the shares are being offered by Seaport Therapeutics. In addition, Seaport Therapeutics has granted the underwriters a 30-day option to buy an additional 2,124,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions. The shares ar...
View stock analysis, news, and events for Puretech Health Plc